Penserra Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Penserra Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-142	Closed	-$6K	–	1583
2021 Q3	$6K	Buy	142 +1	+0.7%	+$49	﹤0.01%	1403
2021 Q2	$7K	Buy	141 +1	+0.7%	+$59	﹤0.01%	1301
2021 Q1	$10K	Buy	140 +35	+33%	+$3.64K	﹤0.01%	1037
2020 Q4	$11K	Buy	105 +66	+169%	+$6.02K	﹤0.01%	919
2020 Q3	$3K	Buy	+39	New	+$4.43K	﹤0.01%	893

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Penserra Capital Management's SYRS Position: Q4 2021 in Review

Penserra Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 142 shares — an estimated $6K sold.

Penserra Capital Management first reported a position in SYRS in Q3 2020 and held it in 5 quarters. The position peaked at $11K in Q4 2020. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

Penserra Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 142 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $6K.
Penserra Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q4 2020.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.